At the core of MD Anderson’s approach to exceptional patient care is a virtuous cycle of innovation that's grounded in collaboration, connectivity and data-based science. Our unique environment and vast resources accelerate novel concepts faster than ever before by offering leading scientific minds close proximity to our clinics to ease collaboration with our renowned clinicians and our patient partners.
At the 2024 American Association for Cancer Research Annual Meeting, our experts will showcase their pacesetting research and join colleagues from across the globe for discussion on the latest advances in cancer science.
Below are highlights from our presentations, details about onsite networking opportunities with our experts and information on open research positions at MD Anderson.
Featured Articles
Trio of studies highlights promising early results with new cancer therapies and targets
Three early-phase clinical studies presented by researchers from MD Anderson Cancer Center at the American Association for Cancer Research Annual Meeting 2024 show promising initial data for patients with lymphoma, gastric or gastroesophageal junction cancers, and specific molecularly selected tumors.
PARP1-selective inhibitor demonstrates early efficacy in breast cancers with DNA repair defects
The first-in-class PARP1-selective inhibitor saruparib demonstrated encouraging early efficacy and a favorable safety profile in patients with homologous recombination repair (HRR)-deficient breast cancers, according to results from the Phase I/II PETRA trial led by researchers at The University of Texas MD Anderson Cancer Center.
MD Anderson Research Highlights AACR 2024 Special Edition
Featuring combination therapies for AML and lung cancer, insights into treatment resistance, the role of tumor microbiomes in immunity, and improved HPV screening.
Meet the Experts
Visit us at Booth 1239 to discuss hot topics and emerging trends with leading minds in cancer science.
Sunday, April 7
1–4 p.m. PT
MD Anderson President
1:30–2 p.m. PT
The Institute for Data Science in Oncology
Arjun Bhattacharya, Ph.D.
Affiliate, Institute for Data Science Oncology
Assistant Professor, Epidemiology
David Jaffray, Ph.D.
Director, Institute for Data Science Oncology
Senior Vice President and Chief Technology and Digital Officer
Professor, Radiation Physics and Imaging Physics
J. Jack Lee, Ph.D.
Affiliate, Institute for Data Science Oncology
Professor, Biostatistics
Han Liang, Ph.D.
Affiliate, Institute for Data Science Oncology
Professor, Bioinformatics and Computational Biology
2–2:30 p.m. PT
Synergies in Immunology
Michael Curran, Ph.D.
Associate Professor, Immunology
Linghua Wang, M.D, Ph.D.
Associate Professor, Genomic Medicine
3–3:30 p.m. PT
Discovery Research at MD Anderson
Rugang Zhang, Ph.D.
Professor, Experimental Therapeutics
Monday, April 8
12–12:30 p.m. PT
Career Opportunities at MD Anderson
Giulio Draetta, M.D., Ph.D.
Chief Scientific Officer
Professor, Genomic Medicine
Jennifer Litton, M.D.
Vice President, Clinical Research
Professor, Breast Medical Oncology
12:30–1 p.m. PT
Drug Discovery and Development at MD Anderson
Tim Heffernan, Ph.D.
Vice President, Oncology Research
Timothy Yap, M.D., Ph.D.
Professor, Investigational Cancer Therapeutics
Vice President, Therapeutics Discovery Division
Associate Director of Translational Research, Khalifa Institute for Personalized Cancer Therapy
1–1:30 p.m. PT
Learning from Our Patients: Translational Molecular Pathology (Part 1)
George Calin, M.D., Ph.D.
Professor, Translational Molecular Pathology
Subrata Sen, Ph.D.
Professor, Translational Molecular Pathology
1–1:30 p.m. PT
Mapping the Pre-Cancer Atlas
Nick Navin, Ph.D.
Professor, Systems Biology
Director, CPRIT Single Cell Genomics Center
Co-Director, Advanced Technology Genomics Core
Linghua Wang, M.D., Ph.D.
Associate Professor, Genomic Medicine
1:30–2 p.m. PT
Emerging Frontiers in Cellular Therapies
Samer Srour, M.B.Ch.B.
Assistant Professor, Stem Cell Transplantation
3–3:30 p.m. PT
The Microbiome and Cancer
Carrie Daniel-MacDougall, Ph.D.
Associate Professor, Epidemiology
Faculty Director, Bionutrition Research Core
Florencia McAllister, M.D.
Associate Professor, Clinical Cancer Prevention
Jennifer McQuade, M.D.
Associate Professor, Melanoma Medical Oncology
Michael White, M.D.
Assistant Professor, Colon & Rectal Surgery
4–4:30 p.m. PT
Early Phase Clinical Trials at MD Anderson
David Hong, M.D.
Deputy Chair, Investigational Cancer Therapeutics
Funda Meric-Bernstam, M.D.
Professor, Breast Surgical Oncology
Medical Director, Khalifa Institute for Personalized Cancer Therapy
Tuesday, April 9
1–1:30 p.m. PT
Cancer Neuroscience: An Emerging Integrative Field (Part 1)
Jian Hu, M.D.
Associate Professor, Cancer Biology
2:30–3 p.m. PT
Learning from Our Patients: Translational Molecular Pathology (Part 2)
Humam Kadara, Ph.D.
Professor, Translational Molecular Pathology
Ignacio Wistuba, M.D.
Professor, Translational Molecular Pathology
3–3:30 p.m. PT
Functional Proteomics: Revealing the Role of Protein in Tumor Development
Yiling Lu, M.D.
Professor, Genomic Medicine
Director, Functional Proteomics RPPA Core
3:30–4 p.m. PT
Cancer Neuroscience: An Emerging Integrative Field (Part 2)
Moran Amit, M.D., Ph.D.
Assistant Professor, Head and Neck Surgery
4–4:30 p.m. PT
Insights on Myelodysplastic Syndromes Progression and Novel Therapies
Simona Colla, Ph.D.
Associate Professor, Leukemia
Our research by the numbers
$1.2B
invested in research
1,568
clinical trials
90
patents awarded
From Sept. 1, 2022 to Aug. 31, 2023
Education and Training at MD Anderson
MD Anderson academic programs are competitive and comprehensive. We offer educational opportunities from undergraduate degrees to postdoctoral training.
James P. Allison Institute
The James P. Allison Institute is dedicated to advancing exceptional discovery, translational and clinical research to integrate immunobiology across disciplines and unlock the full potential of science and medicine for human health. The institute builds upon the legacy of its namesake, James P. Allison, Ph.D., who was awarded the 2018 Nobel Prize in Physiology or Medicine for his fundamental discoveries in T cell biology and his invention of ipilimumab, the first immune checkpoint inhibitor to treat cancer.
Therapeutics Discovery
Our Therapeutics Discovery team consists of dedicated cancer researchers, doctors, drug developers and scientific experts. We develop small molecule drugs, biologics and cellular therapies without the bottlenecks that hamper traditional drug development.
We're inspired by the needs of our patients and guided by the expertise of MD Anderson clinicians. We don't bring the “bench to bedside” – we start with the bench at the bedside – with each patient and their cancer.
Why Houston?
As America's fourth largest city, Houston has a lot to offer. Find out why Houston is a hub for scientific and medical excellence.
